For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 180d
$56.18
Thesis
CRISPR Therapeutics commercialized one of the first approved CRISPR-based medicines and is extending editing into in vivo and immuno-oncology programs. An approved therapy plus a deep pipeline anchors a leading position in gene editing.
Catalysts
- Casgevy commercial ramp and patient starts
- In vivo editing program readouts
- Cell-therapy and cardiovascular pipeline progress